Alterity Therapeutics has launched the Phase II clinical trial of its lead candidate, ATH434, to treat patients with multiple system atrophy (MSA), a rare neurodegenerative disease, in New Zealand.
The trial is currently open for subject enrolment, the company noted.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A small molecule, ATH434 is intended to lower the toxic build-up of α-synuclein, a pathological hallmark of MSA and protect nerve cells by reinstating normal iron balance in the brain.
The double-blind, placebo-controlled, randomised trial will analyse ATH434 in subjects with early-stage MSA.
It will enrol nearly 60 adult subjects, who will be given one of two doses of ATH434 or a placebo.
The trial will analyse the impact of the treatment with ATH434 on imaging and protein biomarkers, such as aggregating α-synuclein and excess iron, which are key contributors to MSA pathology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataClinical and biomarker endpoints will aid in a thorough analysis of ATH434’s efficacy and characterisation of safety and pharmacokinetics.
Trial subjects will be treated for a year, offering a chance to identify changes in efficacy endpoints to streamline the design of a definitive Phase III trial.
Alterity Therapeutics CEO David Stamler said: “The advancement of our ATH434 programme underscores our commitment to bring a much-needed treatment to individuals with MSA.
“The opening of enrolment for our Phase II in New Zealand is an important first step for this clinical programme and I am grateful to our team and our investigators who supported the launch of the trial.
“Over the course of this year, we will expand the trial into other regions globally.”
In a Phase I trial, ATH434 was found to be well-tolerated, orally bioavailable and attained brain levels in line with efficacious levels in animal models of MSA, with the goal of resonating function in people with MSA and other Parkinsonian disorders.
